Amicus Therapeutics (NASDAQ:FOLD – Get Rating) had its price target increased by Bank of America from $16.00 to $17.00 in a research report report published on Monday morning, The Fly reports. Bank of America currently has a buy rating on the biopharmaceutical company’s stock. Several other brokerages also recently weighed in on FOLD. UBS Group […]
StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) from a hold rating to a buy rating in a research note published on Monday morning. FOLD has been the topic of several other research reports. BTIG Research boosted their price target on shares of Amicus Therapeutics from $14.00 to $16.00 and gave the company […]
StockNews.com cut shares of Ardelyx (NASDAQ:ARDX – Get Rating) from a buy rating to a hold rating in a research note published on Monday morning. Other equities research analysts have also recently issued research reports about the company. Cantor Fitzgerald boosted their price objective on Ardelyx from $1.60 to $3.00 in a research note on […]
Amicus Therapeutics (NASDAQ:FOLD – Get Rating) had its target price lifted by investment analysts at Bank of America from $16.00 to $17.00 in a research note issued to investors on Monday, The Fly reports. Bank of America‘s price objective would indicate a potential upside of 53.43% from the company’s current price. Several other equities research […]
StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Get Rating) from a hold rating to a buy rating in a research note published on Monday. FOLD has been the subject of several other reports. UBS Group raised their target price on Amicus Therapeutics from $15.00 to $17.00 and gave the stock a buy rating in […]